This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Imlifidase

  • is an IgG-degrading enzyme derived from Streptococcus pyogenes
  • is a novel agent that cleaves all four human subclasses of IgG and has therapeutic potential for HLA desensitization in kidney transplantation and antibody-mediated rejection
  • is a recombinant cysteine protease derived from S. pyogenes produced recombinantly in Escherichia coli which has the capacity to cleave all four human subclasses of IgG with precise specificity (1)

NICE guidance (2):

Imlifidase is recommended as a desensitisation treatment option for adults who:

  • are waiting for a kidney transplant from a deceased donor
  • are highly sensitised to human leukocyte antigens (HLA)
  • have a positive crossmatch with the donor and are unlikely to have a transplant under the available kidney allocation system (including prioritisation programmes for highly sensitised people)

It is recommended only if:

  • a maximum of 1 dose is given
  • it is given in a specialist centre with experience of treating high sensitisation to HLA
  • the company provides imlifidase according to the commercial arrangement

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.